Seres Therapeutics (NASDAQ:MCRB) – Cantor Fitzgerald reduced their FY2019 earnings per share estimates for shares of Seres Therapeutics in a report released on Tuesday, May 22nd. Cantor Fitzgerald analyst W. Tanner now anticipates that the biotechnology company will earn ($2.18) per share for the year, down from their previous estimate of ($2.12).
Seres Therapeutics (NASDAQ:MCRB) last released its earnings results on Wednesday, May 9th. The biotechnology company reported ($0.69) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.06. The company had revenue of $3.97 million during the quarter, compared to the consensus estimate of $3.00 million. Seres Therapeutics had a negative return on equity of 150.44% and a negative net margin of 277.79%.
A number of other research firms also recently commented on MCRB. BidaskClub upgraded Seres Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 24th. Zacks Investment Research upgraded Seres Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, March 7th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $17.89.
Seres Therapeutics opened at $8.05 on Thursday, according to Marketbeat Ratings. The stock has a market capitalization of $324.41 million, a P/E ratio of -3.64 and a beta of 0.49. The company has a quick ratio of 3.60, a current ratio of 3.60 and a debt-to-equity ratio of 0.85. Seres Therapeutics has a 12 month low of $6.65 and a 12 month high of $17.42.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Arrowstreet Capital Limited Partnership bought a new stake in Seres Therapeutics in the fourth quarter valued at about $143,000. Wells Fargo & Company MN increased its holdings in shares of Seres Therapeutics by 107.2% in the fourth quarter. Wells Fargo & Company MN now owns 29,183 shares of the biotechnology company’s stock worth $296,000 after acquiring an additional 15,097 shares in the last quarter. A.R.T. Advisors LLC increased its holdings in shares of Seres Therapeutics by 141.3% in the first quarter. A.R.T. Advisors LLC now owns 45,952 shares of the biotechnology company’s stock worth $337,000 after acquiring an additional 26,909 shares in the last quarter. Lakeview Capital Partners LLC bought a new stake in shares of Seres Therapeutics in the fourth quarter worth about $346,000. Finally, Virtus Fund Advisers LLC bought a new stake in shares of Seres Therapeutics in the fourth quarter worth about $358,000. Institutional investors and hedge funds own 79.54% of the company’s stock.
In related news, insider John G. Aunins sold 14,279 shares of the company’s stock in a transaction dated Wednesday, April 25th. The stock was sold at an average price of $7.58, for a total value of $108,234.82. Following the completion of the sale, the insider now owns 184,485 shares in the company, valued at $1,398,396.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 41.90% of the company’s stock.
About Seres Therapeutics
Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which is in Phase III clinical study to treat multiply recurrent Clostridium difficile infection (CDI).
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.